|
시장보고서
상품코드
2096946
로봇 수술 시장 - 세계 예측(2026-2032년)Robotic Surgery Market - Global Forecast 2026-2032 |
||||||
360iResearch
로봇 수술 시장은 2032년까지 연평균 복합 성장률(CAGR) 13.78%로 성장해 302억 6,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 122억 5,000만 달러 |
| 추정 연도(2026년) | 138억 6,000만 달러 |
| 예측 연도(2032년) | 302억 6,000만 달러 |
| CAGR(%) | 13.78% |
로봇 수술은 틈새 수술실 기능에서 비뇨기과, 산부인과, 일반외과, 심장흉부외과, 대장직장외과, 정형외과, 뇌신경외과, 두경부외과에 이르는 최소 침습 수술의 핵심 축으로 전환되고 있습니다. 이 기술은 외과의사가 조작하는 로봇 팔, 고해상도 3D 시각화, 손떨림 보정, 손목 가동식 기구, 내비게이션, 영상 통합, 그리고 점점 더 긴밀하게 연계되고 있는 디지털 수술실 워크플로우를 결합하고 있습니다. 그 임상적 가치는 수술의 유형, 환자 프로파일, 외과의사의 경험, 그리고 치료 경로에 따라, 특정 개복 수술법과 비교했을 때 정밀도, 제한된 해부학적 접근, 안정적인 시각화, 재현성 있는 기구 움직임이 더 작은 절개, 출혈량 감소, 입원 기간 단축, 그리고 조기 회복을 가능하게 하는 경우에 가장 두드러지게 나타납니다.
로봇 수술 분야에서는 몇 가지 혁신적인 변화가 일어나고 있습니다. 첫째, 업계는 단일 플랫폼 채택에서 경쟁이 더욱 치열하고 수술 분야에 특화된 환경으로 전환되고 있습니다. 연조직 수술, 정형외과적 재건술, 관강 내 수술, 현미경 수술 및 영상 유도 하 중재 수술을 위해 설계된 시스템이 등장하고 있습니다. 이러한 다양화로 인해 병원들은 전문 분야와의 적합성, 임상적 근거, 설정 시간, 기구, 외과의사의 작업 효율성, 그리고 기존 수술실 인프라와의 통합성을 바탕으로 플랫폼을 평가했습니다.
인공지능(AI)은 로봇 수술의 전체 밸류체인에 걸쳐 누적 영향력을 행사하고 있지만, 현재의 표준 치료법은 자율 수술이 아닌 외과의사 주도 수술이 여전히 주류를 이루고 있습니다. AI를 활용한 기능은 수술 전 계획, 수술 중 영상 분석, 해부학적 구조 인식, 수술 영상 분석, 워크플로우 분류, 기구 추적 및 수술 후 결과 분석에서 점점 더 중요해지고 있습니다. 이러한 도구는 적절한 임상 및 규제 프레임워크 내에서 검증된다면, 임상의가 수술 절차의 편차를 파악하거나, 교육 피드백을 지원하거나, 사례 검토를 개선하거나, 의사결정을 강화하는 데 도움이 될 것입니다.
아시아태평양은 로봇 수술 도입에 있어 가장 활기찬 지역 중 하나입니다. 이는 3차 의료 인프라 확충, 최소 침습 수술 건수 증가, 첨단 의료 기술에 대한 정부 투자, 그리고 일본, 중국, 한국, 인도, 호주 등 국가들의 고령화에 따른 강력한 수요에 힘입은 것입니다. 이 지역의 도입 현황은 지역별로 차이가 있으며, 선진적인 도시 지역 병원이 도입을 주도하고 있는 반면, 보다 광범위한 보급은 연수 체계, 보험 환급 제도, 자금 조달, 현지 제조 능력 및 국내 기술 개발에 좌우되고 있습니다.
아세안(ASEAN)은 싱가포르, 태국, 말레이시아, 인도네시아, 베트남, 필리핀이 첨단 병원 인프라와 최소 침습 수술 연수 체계를 강화하고 있어 로봇 수술의 중요한 성장 거점으로 부상하고 있습니다. 도입은 의료 관광, 민간 의료 투자, 그리고 지역의 우수한 의료 센터에 의해 뒷받침되고 있지만, 비용 대비 효과, 보험 환급, 공립 병원 접근성, 숙련된 인력 확보는 회원국 간에 여전히 중요한 차이 요인으로 작용하고 있습니다.
미국은 선진적인 병원 인프라, 충실한 외과 의사 연수 프로그램, 환자의 폭넓은 인식, 그리고 비뇨기과, 산부인과, 일반외과, 흉부외과, 대장직장외과, 정형외과에 이르는 로봇 플랫폼의 통합을 통해 로봇 수술 활용 분야에서 세계를 선도하는 국가가 되었습니다. 캐나다의 도입 현황은 공공 의료 자금, 주 정부 차원의 조달, 대학 병원의 주도, 그리고 임상 성과와 시스템 효율성에 대한 신중한 평가에 의해 형성되고 있습니다. 멕시코는 민간 병원 네트워크, 국경을 초월한 의료 수요, 전문센터를 통해 발전하고 있는 반면, 브라질은 주요 대도시권 병원, 비뇨기과 및 일반외과 프로그램, 그리고 확대되는 외과의사 교육 이니셔티브에 힘입어 라틴아메리카에서 가장 두드러진 로봇 수술 도입국이 되었습니다.
업계 리더는 임상 결과, 수술실 효율성, 외과의사의 도입, 그리고 환자 중심 치료를 연결하는 근거 기반의 로봇 수술 전략을 우선시해야 합니다. 병원 및 의료 시스템은 수술법 선정, 자격 인증, 연수 프로그램, 환자 안전 프로토콜, 장비 사용 현황, 그리고 치료 성과 보고를 담당하는 다직종으로 구성된 로봇 수술 거버넌스 위원회를 설립해야 합니다. 플랫폼을 선정할 때는 전문 분야별 요구 사항, 기구의 수명 주기 비용, 서비스 신뢰성, 상호 운용성, 데이터 보안, 영상 진단과의 호환성, 멸균 워크플로우, 그리고 디지털 헬스 인프라와의 통합 용이성을 고려해야 합니다.
본 요약본은 신뢰할 수 있는 공공 및 기관 출처에서 얻은 검증되고 데이터로 뒷받침되는 정보에 초점을 맞춘 구조화된 2차 조사 방법론을 사용하여 작성되었습니다. 이 조사 접근 방식은 동료 심사를 거친 임상 문헌, 규제 지침, 병원 기술 평가 관련 간행물, 외과학회 지침, 공중보건 시스템 문서, 정부 의료 전략, 의료기기 안전성 정보 및 인정된 임상 결과 연구를 중점적으로 다룹니다. 이러한 인사이트는 임상적, 운영적, 지역적, 기술적 관점에 걸친 일관성을 확보하기 위해 상호 검증을 통해 통합되었습니다.
로봇 수술은 최소 침습적 접근법, 시야 확보, 기구의 정밀도, 그리고 디지털 워크플로우의 지능을 결합하여 현대 외과 의료를 재정의하고 있습니다. 그 최대의 가치는 의료 시스템이 기술 도입을 임상적 근거, 외과의사 교육, 수술실 효율성, 환자 선정 및 측정 가능한 결과와 조화시킬 때 발휘됩니다. 로봇 플랫폼의 다양화가 진행되고, AI를 활용한 수술 인텔리전스가 성숙해짐에 따라, 이 분야는 하드웨어 중심의 도입에서 통합된 디지털 수술 생태계로 전환되고 있습니다.
The Robotic Surgery Market is projected to grow by USD 30.26 billion at a CAGR of 13.78% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 12.25 billion |
| Estimated Year [2026] | USD 13.86 billion |
| Forecast Year [2032] | USD 30.26 billion |
| CAGR (%) | 13.78% |
Robotic surgery is moving from a niche operating room capability to a core pillar of minimally invasive surgery across urology, gynecology, general surgery, cardiothoracic surgery, colorectal surgery, orthopedics, neurosurgery, and head-and-neck procedures. The technology combines surgeon-controlled robotic arms, high-definition 3D visualization, tremor filtration, wristed instruments, navigation, imaging integration, and increasingly connected digital operating room workflows. Its clinical value is most evident where precision, confined anatomical access, stable visualization, and repeatable instrument movement can support smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery when compared with selected open surgical approaches, depending on procedure type, patient profile, surgeon experience, and care pathway.
Demand for robotic-assisted surgery is being shaped by the global shift toward value-based care, pressure to reduce perioperative complications, expansion of ambulatory and short-stay surgical models, and rising patient preference for less invasive treatment options. Hospitals and surgical centers are also assessing robotic surgery platforms through the lens of utilization efficiency, surgeon training, instrument economics, interoperability, cybersecurity, maintenance requirements, and evidence-based clinical outcomes. As the robotic surgery ecosystem matures, purchasing decisions are no longer driven solely by hardware capability; they increasingly depend on total procedural value, clinical governance, credentialing standards, data integration, and measurable improvements in operating room performance.
The robotic surgery landscape is undergoing several transformative shifts. First, the industry is moving from single-platform adoption toward a more competitive and procedure-specific environment, with systems designed for soft-tissue surgery, orthopedic reconstruction, endoluminal procedures, microsurgery, and image-guided interventions. This diversification is encouraging hospitals to evaluate platforms based on specialty fit, clinical evidence, setup time, instrumentation, surgeon ergonomics, and integration with existing operating room infrastructure.
Second, robotic surgery is becoming increasingly data-driven. Modern systems generate surgical workflow data, instrument usage data, video records, and performance metrics that can support training, quality improvement, peer review, and operational planning. This is accelerating interest in digital surgery, surgical intelligence, remote proctoring, simulation-based education, and standardized credentialing. Third, care delivery models are changing as health systems seek to expand minimally invasive procedures into outpatient and same-day discharge pathways where clinically appropriate. This places new emphasis on compact system design, faster turnover, cost-effective instruments, and multidisciplinary perioperative protocols.
Fourth, regulatory scrutiny and evidence requirements are intensifying. Device approvals, post-market surveillance, real-world evidence generation, cybersecurity controls, usability engineering, and transparency around patient outcomes are becoming central to adoption. Finally, the workforce dimension is pivotal: robotic surgery programs increasingly require structured training for surgeons, nurses, anesthesiology teams, sterile processing units, biomedical engineers, and operating room administrators to ensure safe, consistent, and efficient use.
Artificial intelligence is becoming a cumulative force across the robotic surgery value chain, although the current standard of care remains surgeon-directed rather than autonomous surgery. AI-enabled capabilities are increasingly relevant in preoperative planning, intraoperative imaging interpretation, anatomical recognition, surgical video analytics, workflow segmentation, instrument tracking, and postoperative outcome analysis. These tools can help clinicians identify procedural variations, support training feedback, improve case review, and strengthen decision-making when validated within appropriate clinical and regulatory frameworks.
The most immediate impact of AI in robotic-assisted surgery is expected in surgical intelligence rather than full autonomy. Video-based analytics can support objective assessment of surgical technique, while machine learning models can help analyze large volumes of procedural data to identify patterns associated with efficiency, complications, or learning curves. AI-assisted imaging can also enhance navigation and tissue differentiation in selected use cases, particularly when combined with fluorescence imaging, advanced visualization, or real-time guidance tools.
However, AI adoption in robotic surgery requires careful governance. Clinical validation, bias mitigation, explainability, patient consent, data privacy, cybersecurity, interoperability, and liability frameworks remain essential. Hospitals and policymakers are likely to prioritize AI tools that demonstrate reproducible clinical utility, integrate into existing workflows, and complement surgeon expertise without increasing cognitive burden or procedural risk.
Asia-Pacific is one of the most dynamic regions for robotic surgery adoption, supported by expanding tertiary care infrastructure, rising minimally invasive surgery procedure volumes, government investments in advanced medical technology, and strong demand from aging populations in countries such as Japan, China, South Korea, India, and Australia. The region's adoption pattern is uneven, with advanced urban hospitals leading implementation while broader access depends on training capacity, reimbursement pathways, capital funding, local manufacturing capability, and domestic technology development.
North America remains a highly influential robotic surgery region because of mature hospital networks, high awareness of minimally invasive surgery, established surgeon training ecosystems, and a strong base of academic medical centers using robotic platforms for complex procedures. Adoption is closely tied to clinical evidence, reimbursement alignment, hospital productivity, patient outcomes, and operating room capacity management, with growing interest in ambulatory robotic surgery and data-driven operating room optimization.
Latin America is advancing gradually, with Brazil and Mexico serving as important hubs for specialized robotic surgery programs. Regional adoption is influenced by private hospital investment, medical tourism, surgeon fellowship programs, and the need to expand access beyond major metropolitan centers. Europe demonstrates broad but regulated adoption, shaped by national health technology assessment processes, public hospital procurement, clinical guidelines, medical device regulation, and cross-border research collaboration. Countries such as Germany, France, Italy, Spain, and the United Kingdom continue to prioritize evidence-based robotic surgery implementation.
The Middle East is investing in robotic surgery as part of broader healthcare modernization, specialty hospital development, and medical excellence initiatives, particularly in Gulf economies. Adoption is supported by advanced hospital infrastructure, international clinical partnerships, and policy efforts to retain patients seeking complex care. Africa remains earlier in its robotic surgery journey, with access concentrated in select tertiary facilities and private hospitals; progress depends on workforce training, affordability, maintenance support, biomedical engineering capacity, and integration with wider surgical capacity-building programs.
ASEAN is becoming an important robotic surgery growth corridor as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines strengthen advanced hospital infrastructure and minimally invasive surgical training. Adoption is supported by medical tourism, private healthcare investment, and regional centers of excellence, although affordability, reimbursement, public hospital access, and skilled workforce availability remain key differentiators across member countries.
The GCC is demonstrating strong interest in robotic surgery through healthcare transformation strategies, specialist hospital expansion, and investment in premium surgical capabilities. Robotic-assisted procedures align with the region's focus on reducing outbound medical travel, improving complex care access, and building high-acuity clinical programs. The European Union emphasizes regulatory compliance, clinical evidence, procurement discipline, data protection, and cross-country quality standards, making it a key environment for evidence-based robotic surgery deployment and post-market monitoring.
BRICS countries show diverse but strategically important adoption patterns. China and India are expanding access through large hospital networks, surgeon training, and domestic innovation, while Brazil and South Africa are developing specialized robotic surgery centers within broader surgical modernization efforts; Russia's adoption is shaped by hospital infrastructure, public procurement, and technology localization priorities. The G7 continues to influence robotic surgery through advanced healthcare systems, surgical research, regulatory frameworks, clinical training, and digital health integration. NATO countries, while not a healthcare bloc, include many advanced medical systems where robotic surgery intersects with trauma care innovation, military medicine research, telemedicine, remote support, and resilient surgical infrastructure planning.
The United States is a leading country for robotic surgery utilization due to advanced hospital infrastructure, extensive surgeon training programs, broad patient awareness, and integration of robotic platforms across urology, gynecology, general surgery, thoracic surgery, colorectal surgery, and orthopedics. Canada's adoption is shaped by public healthcare funding, provincial procurement, academic hospital leadership, and careful evaluation of clinical outcomes and system efficiency. Mexico is advancing through private hospital networks, cross-border healthcare demand, and specialty centers, while Brazil is the most prominent robotic surgery adopter in Latin America, supported by major metropolitan hospitals, urology and general surgery programs, and growing surgeon education initiatives.
The United Kingdom applies a structured approach to robotic surgery adoption through clinical governance, public health system procurement, and specialist surgical networks. Germany benefits from strong surgical innovation, engineering capability, and high-quality hospital infrastructure, making it a key European adopter across multiple specialties. France emphasizes evidence-based implementation and health system evaluation, while Italy and Spain continue to expand robotic programs in high-volume specialties such as urology, gynecology, colorectal surgery, and thoracic surgery. Russia's adoption is influenced by regional hospital modernization, training availability, public procurement, and technology access.
China is rapidly strengthening robotic surgery capabilities through hospital expansion, domestic technology development, surgeon training, and government support for high-end medical equipment. India is gaining momentum as large private hospitals, academic institutions, and specialty centers expand robotic-assisted procedures, although affordability, reimbursement, and geographic access remain important barriers. Japan combines an aging population, strong surgical standards, and advanced medical technology adoption, particularly in urology, gastrointestinal surgery, and thoracic procedures. Australia's adoption is concentrated in major public and private hospitals with emphasis on clinical outcomes, procurement discipline, and specialist training. South Korea is a highly advanced robotic surgery country, supported by strong hospital technology adoption, surgeon expertise, digital health readiness, and active use of robotic systems in complex minimally invasive procedures.
Industry leaders should prioritize evidence-led robotic surgery strategies that connect clinical outcomes, operating room efficiency, surgeon adoption, and patient-centered care. Hospitals and health systems need to build multidisciplinary robotic surgery governance committees responsible for procedure selection, credentialing, training pathways, patient safety protocols, equipment utilization, and outcome reporting. Platform selection should account for specialty requirements, instrument lifecycle costs, service reliability, interoperability, data security, imaging compatibility, sterilization workflows, and ease of integration with digital health infrastructure.
Manufacturers and technology developers should focus on improving affordability, modularity, system uptime, haptic feedback, imaging integration, AI-enabled workflow support, and training ecosystems. They should also strengthen real-world evidence programs and collaborate with clinical users to validate performance across diverse patient populations and surgical specialties. Providers should expand simulation-based training, proctoring, structured mentoring, and continuous competency assessment to reduce learning-curve variability.
Policymakers and payers should support transparent outcome evaluation, equitable access, and reimbursement models that recognize value when robotic surgery improves measurable clinical or operational results. Across the ecosystem, leaders should treat cybersecurity, ethical AI governance, patient consent, and data interoperability as strategic requirements rather than technical afterthoughts.
This executive summary is developed using a structured secondary research methodology focused on verified, data-backed information from credible public and institutional sources. The research approach emphasizes peer-reviewed clinical literature, regulatory guidance, hospital technology assessment publications, surgical society guidelines, public health system documents, government healthcare strategies, medical device safety communications, and recognized clinical outcome studies. Insights are synthesized through cross-validation to ensure consistency across clinical, operational, regional, and technology perspectives.
The methodology avoids unsupported claims and excludes market sizing, market share, and forecasting. Instead, it focuses on adoption drivers, clinical use cases, regulatory dynamics, technology shifts, regional healthcare infrastructure, training requirements, and strategic implications for robotic-assisted surgery. Country and regional insights are interpreted through observable factors such as healthcare modernization, tertiary hospital capacity, minimally invasive surgery penetration, reimbursement environment, surgeon education, regulatory pathways, and digital operating room readiness.
The analysis also considers limitations in robotic surgery evidence, including variation by procedure type, surgeon experience, patient selection, comparator technique, institutional workflow, and follow-up duration. This ensures that conclusions remain practical, balanced, and aligned with evidence-based healthcare decision-making.
Robotic surgery is redefining modern surgical care by combining minimally invasive access, enhanced visualization, instrument precision, and digital workflow intelligence. Its strongest value emerges when health systems align technology adoption with clinical evidence, surgeon training, operating room efficiency, patient selection, and measurable outcomes. As robotic platforms diversify and AI-enabled surgical intelligence matures, the field is shifting from hardware-centered adoption to integrated digital surgery ecosystems.
Regional momentum is broad but uneven, with North America, Europe, and advanced Asia-Pacific markets leading structured implementation, while Latin America, the Middle East, and Africa progress through targeted investments and specialized centers. Group and country-level dynamics show that adoption depends not only on purchasing capacity but also on reimbursement, governance, training, infrastructure, service support, and long-term maintenance readiness.
For industry leaders, the next phase of robotic surgery will be defined by affordability, interoperability, clinical validation, AI governance, cybersecurity, and equitable access. Organizations that combine innovation with evidence-based deployment and operational discipline will be best positioned to advance safer, more efficient, and more patient-centered surgical care.